Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.45 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | PKM | P14618 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL309819 | 0.93 | IDH1 (0.43) | EPHX2MEN1KMT2AGAAGBA1 | |
| SCHEMBL309950 | 0.89 | EPHX2 (0.47) | EPHX2TRPV4MEN1KMT2AGAA | |
| SCHEMBL308880 | 0.87 | EPHX2 (0.47) | EPHX2MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL309656 | 0.86 | MMP1 (0.42) | EPHX2MEN1KMT2AGAAMAPT | |
| SCHEMBL1430100 | 0.83 | TRPV4 (0.41) | EPHX2TRPV4MEN1KMT2AGAA | |
| SCHEMBL308446 | 0.83 | TRPV4 (0.41) | EPHX2TRPV4MEN1KMT2AGAA | |
| SCHEMBL2832484 | 0.73 | EPHX2 (0.48) | EPHX2TRPV4MEN1KMT2AGAA | |
| SCHEMBL20003707 | 0.72 | TRPV4 (0.52) | EPHX2TRPV4MEN1KMT2AALDH1A1 | |
| SCHEMBL308314 | 0.70 | EPHX2 (0.46) | EPHX2TRPV4MEN1KMT2AGAA | |
| SCHEMBL11953530 | 0.68 | KMT2A (0.38) | EPHX2TRPV4MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093249-B2 | Pyrazolo[1,5-A]pyrimidine-carbonyl-piperazine derivatives | Convergence Pharmaceuticals Limited (GB) | 2012-01-10 | — | — | US | disclosed |
| US-20100016330-A1 | Novel Derivatives | Convergence Pharmaceuticals Limited (GB) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016330-A1 | Novel Derivatives | CACNB2, CACNA1B, CACNA1D | EPHX2 3915/4885TRPV4 44/4885MEN1 4136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.